{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:38:55Z","timestamp":1791866335076,"version":"4.3.4"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus Kiel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00134-024-07576-4","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T13:36:56Z","timestamp":1724420216000},"page":"1459-1469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8789-0285","authenticated-orcid":false,"given":"Torsten","family":"Schroeder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjark","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Fransecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Valerius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Schub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Pott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"St\u00f6lzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"issue":"6165","key":"7576_CR1","first-page":"1432","volume":"342","author":"J Couzin-Frankel","year":"2013","unstructured":"Couzin-Frankel J (2013) Breakthrough of the year 2013. Cancer Immunotherap Sci 342(6165):1432\u20131433","journal-title":"Cancer Immunotherap Sci"},{"issue":"1","key":"7576_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M (2018) Chimeric antigen receptor therapy. N Engl J Med 379(1):64\u201373","journal-title":"N Engl J Med"},{"issue":"1","key":"7576_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M et al (2018) Cytokine release syndrome. J Immunother Cancer 6(1):56\u201370","journal-title":"J Immunother Cancer"},{"issue":"5","key":"7576_CR4","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1016\/S2352-3026(21)00060-0","volume":"8","author":"\u00c9 Azoulay","year":"2021","unstructured":"Azoulay \u00c9, Castro P, Maamar A et al (2021) Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. Lancet Haematol 8(5):e355\u2013e364","journal-title":"Lancet Haematol"},{"issue":"4","key":"7576_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM (2021) CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 11(4):69","journal-title":"Blood Cancer J"},{"issue":"13","key":"7576_CR6","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody S, Devlin SM, Landa J et al (2022) GPRC5D-targeted CAR T cells for myeloma. N Engl J Med 387(13):1196\u20131206","journal-title":"N Engl J Med"},{"issue":"2","key":"7576_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/HS9.0000000000000191","volume":"3","author":"J Garcia Borrega","year":"2019","unstructured":"Garcia Borrega J, G\u00f6del P, R\u00fcger MA et al (2019) In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy. Hemasphere 3(2):191\u2013200","journal-title":"Hemasphere"},{"key":"7576_CR8","doi-asserted-by":"crossref","unstructured":"Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. Int J Mol Sci. 2019;20(6).","DOI":"10.3390\/ijms20061283"},{"key":"7576_CR9","doi-asserted-by":"crossref","unstructured":"Pietrobon V, Todd LA, Goswami A, Stefanson O, Yang Z, Marincola F. Improving CAR T-Cell Persistence. Int J Mol Sci. 2021;22(19).","DOI":"10.3390\/ijms221910828"},{"key":"7576_CR10","doi-asserted-by":"crossref","unstructured":"Honikel MM, Olejniczak SH. Co-Stimulatory Receptor Signaling in CAR-T Cells. Biomolecules. 2022;12(9).","DOI":"10.3390\/biom12091303"},{"issue":"11","key":"7576_CR11","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","volume":"18","author":"KM Cappell","year":"2021","unstructured":"Cappell KM, Kochenderfer JN (2021) A comparison of chimeric antigen receptors containing CD28 versus 4\u20131BB costimulatory domains. Nat Rev Clin Oncol 18(11):715\u2013727","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"7576_CR12","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","volume":"44","author":"JH Esensten","year":"2016","unstructured":"Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA (2016) CD28 Costimulation: From Mechanism to Therapy. Immunity 44(5):973\u2013988","journal-title":"Immunity"},{"key":"7576_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhu L, Zhang H, Chen S, Xiao Y (2022) CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Front Immunol 13:927153","journal-title":"Front Immunol"},{"key":"7576_CR14","doi-asserted-by":"crossref","unstructured":"Cameron J Turtle L-AH, Carolina Berger, Daniel Sommermeyer, Barbara Pender, Emily M Robinson, Katherine Melville, Tanya M Budiarto, Natalia N Steevens, Colette Chaney, Sindhu Cherian, Brent L Wood, Lorinda Soma, Xueyan Chen, Shelly Heimfeld, Michael C Jensen, Stanley R. Riddell, David G Maloney. Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia. Blood. 2015;Volume 126(Issue 23):Page 3773.","DOI":"10.1182\/blood.V126.23.3773.3773"},{"issue":"2 Pt 1","key":"7576_CR15","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1158\/1078-0432.CCR-06-1209","volume":"13","author":"L Bracci","year":"2007","unstructured":"Bracci L, Moschella F, Sestili P et al (2007) Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 13(2 Pt 1):644\u2013653","journal-title":"Clin Cancer Res"},{"issue":"15","key":"7576_CR16","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","volume":"133","author":"KA Hay","year":"2019","unstructured":"Hay KA, Gauthier J, Hirayama AV et al (2019) Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood 133(15):1652\u20131663","journal-title":"Blood"},{"issue":"1\u20132","key":"7576_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.brainresrev.2011.01.002","volume":"67","author":"A Spooren","year":"2011","unstructured":"Spooren A, Kolmus K, Laureys G et al (2011) Interleukin-6, a mental cytokine. Brain Res Rev 67(1\u20132):157\u2013183","journal-title":"Brain Res Rev"},{"issue":"7","key":"7576_CR18","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1182\/bloodadvances.2019001304","volume":"4","author":"SJ Schuster","year":"2020","unstructured":"Schuster SJ, Maziarz RT, Rusch ES et al (2020) Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv 4(7):1432\u20131439","journal-title":"Blood Adv"},{"issue":"4","key":"7576_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant 25(4):625\u2013638","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"7576_CR20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","volume":"15","author":"C Kotch","year":"2019","unstructured":"Kotch C, Barrett D, Teachey DT (2019) Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol 15(8):813\u2013822","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"7576_CR21","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s00277-017-3098-3","volume":"96","author":"WJ Heinz","year":"2017","unstructured":"Heinz WJ, Buchheidt D, Christopeit M et al (2017) Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 96(11):1775\u20131792","journal-title":"Ann Hematol"},{"issue":"1","key":"7576_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-024-00495-6","volume":"13","author":"L Wang","year":"2024","unstructured":"Wang L, Lv Y, Zhou L et al (2024) Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies. Exp Hematol Oncol 13(1):1\u20135","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"7576_CR23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s40425-019-0767-x","volume":"7","author":"H Luo","year":"2019","unstructured":"Luo H, Wang N, Huang L et al (2019) Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy. J Immunother Cancer 7(1):271","journal-title":"J Immunother Cancer"},{"key":"7576_CR24","doi-asserted-by":"crossref","unstructured":"Topp M, Van Meerten T, Houot R, et al. Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed\/Refractory Large B Cell Lymphoma. Blood. 2019;134(Supplement_1):243\u2013243.","DOI":"10.1182\/blood-2019-126081"},{"issue":"20","key":"7576_CR25","first-page":"2430","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN (2023) How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood 141(20):2430\u20132442","journal-title":"Blood"},{"issue":"3","key":"7576_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/MCC.0b013e32834699cd","volume":"17","author":"M Cecconi","year":"2011","unstructured":"Cecconi M, Parsons AK, Rhodes A (2011) What is a fluid challenge? Curr Opin Crit Care 17(3):290\u2013295","journal-title":"Curr Opin Crit Care"},{"key":"7576_CR27","doi-asserted-by":"crossref","unstructured":"Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. Jama. 1995;274(8):639\u2013644.","DOI":"10.1001\/jama.274.8.639"},{"issue":"7","key":"7576_CR28","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","volume":"29","author":"N Gazeau","year":"2023","unstructured":"Gazeau N, Liang EC, Wu QV et al (2023) Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther 29(7):430\u2013437","journal-title":"Transplant Cell Ther"},{"issue":"22","key":"7576_CR29","doi-asserted-by":"publisher","first-page":"5702","DOI":"10.1182\/blood.V128.22.5702.5702","volume":"128","author":"AL Garfall","year":"2016","unstructured":"Garfall AL, Lancaster E, Stadtmauer EA et al (2016) Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide. Blood 128(22):5702\u20135703","journal-title":"Blood"},{"issue":"12","key":"7576_CR30","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","volume":"32","author":"J Gust","year":"2018","unstructured":"Gust J, Taraseviciute A, Turtle CJ (2018) Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies. CNS Drugs 32(12):1091\u20131101","journal-title":"CNS Drugs"},{"key":"7576_CR31","unstructured":"Rees JH. Part IV: Clinical Management of Patients Treated with CAR-T Cells. In: Kr\u00f6ger N. The EBMT\/EHA CAR-T Cell Handbook.2022."},{"issue":"1","key":"7576_CR32","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12245-023-00540-x","volume":"16","author":"S Patel","year":"2023","unstructured":"Patel S, Maria-Rios J, Parikh A, Okorie ON (2023) Diagnosis and management of elevated intracranial pressure in the emergency department. Int J Emerg Med 16(1):72\u201391","journal-title":"Int J Emerg Med"},{"issue":"1","key":"7576_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42466-021-00166-5","volume":"4","author":"N M\u00f6hn","year":"2022","unstructured":"M\u00f6hn N, Bonda V, Grote-Levi L et al (2022) Neurological management and work-up of neurotoxicity associated with CAR T cell therapy. Neurol Res Pract 4(1):1","journal-title":"Neurol Res Pract"},{"issue":"10","key":"7576_CR34","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T (2008) Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112(10):3959\u20133964","journal-title":"Blood"},{"key":"7576_CR35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ejca.2021.10.022","volume":"160","author":"J Lemoine","year":"2022","unstructured":"Lemoine J, Vic S, Houot R (2022) Disease-specific outcomes after chimeric antigen receptor T-cell therapy. Eur J Cancer 160:235\u2013242","journal-title":"Eur J Cancer"},{"issue":"1","key":"7576_CR36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13054-018-2066-1","volume":"22","author":"S Farrokh","year":"2018","unstructured":"Farrokh S, Tahsili-Fahadan P, Ritzl EK, Lewin JJ 3rd, Mirski MA (2018) Antiepileptic drugs in critically ill patients. Crit Care 22(1):153\u2013165","journal-title":"Crit Care"},{"key":"7576_CR37","doi-asserted-by":"crossref","unstructured":"Wehrli M, Gallagher K, Chen YB, et al. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). J Immunother Cancer. 2022;10(1).","DOI":"10.1136\/jitc-2021-003847"},{"issue":"2","key":"7576_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen AD, Parekh S, Santomasso BD et al (2022) Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J 12(2):32","journal-title":"Blood Cancer J"},{"key":"7576_CR39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.intimp.2018.03.018","volume":"58","author":"Q Wang","year":"2018","unstructured":"Wang Q, Gao J, Wu X (2018) Pseudoprogression and hyperprogression after checkpoint blockade. Int Immunopharmacol 58:125\u2013135","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"7576_CR40","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40259-020-00425-y","volume":"34","author":"M Frelaut","year":"2020","unstructured":"Frelaut M, du Rusquec P, de Moura A, Le Tourneau C, Borcoman E (2020) Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy. BioDrugs 34(4):463\u2013476","journal-title":"BioDrugs"},{"issue":"3","key":"7576_CR41","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18(3):e143\u2013e152","journal-title":"Lancet Oncol"},{"issue":"2","key":"7576_CR42","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1097\/RLU.0000000000003870","volume":"47","author":"C Boursier","year":"2022","unstructured":"Boursier C, Perrin M, Bordonne M, Campidelli A, Verger A (2022) Early 18F-FDG PET Flare-up Phenomenon After CAR T-Cell Therapy in Lymphoma. Clin Nucl Med 47(2):e152\u2013e153","journal-title":"Clin Nucl Med"},{"issue":"10","key":"7576_CR43","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1182\/bloodadvances.2020001450","volume":"4","author":"CC Denton","year":"2020","unstructured":"Denton CC, Gange WS, Abdel-Azim H et al (2020) Bilateral retinal detachment after chimeric antigen receptor T-cell therapy. Blood Adv 4(10):2158\u20132162","journal-title":"Blood Adv"},{"issue":"4","key":"7576_CR44","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","volume":"29","author":"J Mahdi","year":"2023","unstructured":"Mahdi J, Dietrich J, Straathof K et al (2023) Tumor inflammation-associated neurotoxicity. Nat Med 29(4):803\u2013810","journal-title":"Nat Med"},{"issue":"7903","key":"7576_CR45","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner RG, Ramakrishna S, Yeom KW et al (2022) GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603(7903):934\u2013941","journal-title":"Nature"},{"issue":"3","key":"7576_CR46","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1182\/blood-2004-08-3198","volume":"106","author":"K Dunleavy","year":"2005","unstructured":"Dunleavy K, Hakim F, Kim HK et al (2005) B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 106(3):795\u2013802","journal-title":"Blood"},{"issue":"10","key":"7576_CR47","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","volume":"54","author":"S Fried","year":"2019","unstructured":"Fried S, Avigdor A, Bielorai B et al (2019) Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant 54(10):1643\u20131650","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"7576_CR48","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS et al (2019) Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 380(1):45\u201356","journal-title":"N Engl J Med"},{"issue":"1","key":"7576_CR49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA et al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol 20(1):31\u201342","journal-title":"Lancet Oncol"},{"issue":"10","key":"7576_CR50","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Subklewe M, Aljurf M et al (2023) Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood 142(10):865\u2013877","journal-title":"Blood"},{"issue":"24","key":"7576_CR51","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski K, Perez A, Sesques P et al (2021) CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood 138(24):2499\u20132513","journal-title":"Blood"},{"key":"7576_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.987965","volume":"12","author":"Y Wang","year":"2022","unstructured":"Wang Y, Song Z, Geng Y et al (2022) The risk factors and early predictive model of hematotoxicity after CD19 chimeric antigen receptor T cell therapy. Front Oncol 12:987965","journal-title":"Front Oncol"},{"issue":"10","key":"7576_CR53","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41408-022-00741-2","volume":"12","author":"KC Miller","year":"2022","unstructured":"Miller KC, Johnson PC, Abramson JS et al (2022) Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. Blood Cancer J 12(10):146","journal-title":"Blood Cancer J"},{"issue":"9","key":"7576_CR54","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jtct.2023.05.012","volume":"29","author":"JA Davis","year":"2023","unstructured":"Davis JA, Sborov DW, Wesson W et al (2023) Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy. Transplant Cell Ther 29(9):567\u2013571","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"7576_CR55","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40265-021-01553-7","volume":"81","author":"J Gilreath","year":"2021","unstructured":"Gilreath J, Lo M, Bubalo J (2021) Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists. Drugs 81(11):1285\u20131305","journal-title":"Drugs"},{"issue":"4","key":"7576_CR56","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/bloodadvances.2022008042","volume":"7","author":"N Gagelmann","year":"2023","unstructured":"Gagelmann N, Wulf GG, Duell J et al (2023) Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA\/DRST study. Blood Adv 7(4):555\u2013559","journal-title":"Blood Adv"},{"issue":"2","key":"7576_CR57","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","volume":"10","author":"J Wat","year":"2022","unstructured":"Wat J, Barmettler S (2022) Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions. J Allergy Clin Immunol Pract 10(2):460\u2013466","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"7576_CR58","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/17474086.2022.2063833","volume":"15","author":"E Kampouri","year":"2022","unstructured":"Kampouri E, Walti CS, Gauthier J, Hill JA (2022) Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians. Expert Rev Hematol 15(4):305\u2013320","journal-title":"Expert Rev Hematol"},{"issue":"8","key":"7576_CR59","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","volume":"10","author":"K Wudhikarn","year":"2020","unstructured":"Wudhikarn K, Palomba ML, Pennisi M et al (2020) Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer J 10(8):79","journal-title":"Blood Cancer J"},{"issue":"3","key":"7576_CR60","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","volume":"128","author":"VG Bhoj","year":"2016","unstructured":"Bhoj VG, Arhontoulis D, Wertheim G et al (2016) Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood 128(3):360\u2013370","journal-title":"Blood"},{"issue":"8","key":"7576_CR61","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood.2019004000","volume":"136","author":"JA Hill","year":"2020","unstructured":"Hill JA, Seo SK (2020) How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood 136(8):925\u2013935","journal-title":"Blood"},{"key":"7576_CR62","unstructured":"Topp M, Feuchtinger T. Part IV Clinical Management of Patients Treated with CAR-T Cells. In: Kr\u00f6ger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H. The EBMT\/EHA CAR-T Cell Handbook2022."},{"issue":"1","key":"7576_CR63","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","volume":"131","author":"JA Hill","year":"2018","unstructured":"Hill JA, Li D, Hay KA et al (2018) Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood 131(1):121\u2013130","journal-title":"Blood"},{"issue":"4","key":"7576_CR64","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/cid\/ciy152","volume":"67","author":"JH Park","year":"2018","unstructured":"Park JH, Romero FA, Taur Y et al (2018) Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells. Clin Infect Dis 67(4):533\u2013540","journal-title":"Clin Infect Dis"},{"issue":"7","key":"7576_CR65","first-page":"438.e431","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines MR, Knight TE, McNerney KO et al (2023) Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transplant Cell Ther 29(7):438.e431-438.e416","journal-title":"Transplant Cell Ther"},{"key":"7576_CR66","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3389\/fimmu.2020.00524","volume":"11","author":"RD Sandler","year":"2020","unstructured":"Sandler RD, Tattersall RS, Schoemans H et al (2020) Diagnosis and Management of Secondary HLH\/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). Front Immunol 11:524","journal-title":"Front Immunol"},{"issue":"2","key":"7576_CR67","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"JI Henter","year":"2007","unstructured":"Henter JI, Horne A, Aric\u00f3 M et al (2007) HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48(2):124\u2013131","journal-title":"Pediatr Blood Cancer"},{"issue":"25","key":"7576_CR68","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","volume":"130","author":"E Bergsten","year":"2017","unstructured":"Bergsten E, Horne A, Aric\u00f3 M et al (2017) Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood 130(25):2728\u20132738","journal-title":"Blood"},{"issue":"6","key":"7576_CR69","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1200\/OP.22.00713","volume":"19","author":"RI Marar","year":"2023","unstructured":"Marar RI, Abbasi MA, Prathivadhi-Bhayankaram S et al (2023) Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy. JCO Oncol Pract 19(6):331\u2013342","journal-title":"JCO Oncol Pract"},{"key":"7576_CR70","doi-asserted-by":"crossref","unstructured":"Nenna A, Carpenito M, Chello C, et al. Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment. Int J Mol Sci. 2022;23(15).","DOI":"10.3390\/ijms23158242"},{"issue":"5","key":"7576_CR71","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jaccao.2022.07.014","volume":"4","author":"S Ganatra","year":"2022","unstructured":"Ganatra S, Dani SS, Yang EH, Zaha VG, Nohria A (2022) Cardiotoxicity of T-Cell Antineoplastic Therapies: JACC: CardioOncology Primer. JACC CardioOncol 4(5):616\u2013623","journal-title":"JACC CardioOncol"},{"issue":"1","key":"7576_CR72","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, Majzner RG, Krenciute G et al (2023) Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol 20(1):49\u201362","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"7576_CR73","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1158\/2159-8290.CD-21-1683","volume":"12","author":"RM Young","year":"2022","unstructured":"Young RM, Engel NW, Uslu U, Wellhausen N, June CH (2022) Next-Generation CAR T-cell Therapies. Cancer Discov 12(7):1625\u20131633","journal-title":"Cancer Discov"},{"issue":"3","key":"7576_CR74","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.2022015526","volume":"141","author":"AD Cohen","year":"2023","unstructured":"Cohen AD, Mateos MV, Cohen YC et al (2023) Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood 141(3):219\u2013230","journal-title":"Blood"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-024-07576-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00134-024-07576-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-024-07576-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T09:07:21Z","timestamp":1725527241000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00134-024-07576-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":74,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["7576"],"URL":"https:\/\/doi.org\/10.1007\/s00134-024-07576-4","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"21 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing fincancial interests or persolal relationships that could have appeared to influence the work reported in this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}